NEW YORK--(BUSINESS WIRE)--Aug. 27, 2009--
Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and
marketer of pharmaceutical products and Nycomed, a privately owned
pharmaceutical company, will host a conference call at 7:15 AM EDT on
Friday, August 28, 2009. Dr. Lawrence Olanoff, President and Chief
Operating Officer of Forest Labs, Dr. Marco Taglietti, President of
Forest Research Institute, Dr. Anders Ullman, Executive Vice President
R&D of Nycomed and Professor Fernando Martinez from the University of
Michigan will discuss the results of the Daxas® Phase III
clinical trials that were published in The Lancet today.
The conference call will be webcast live beginning at 7:15 AM EDT on the
Company's website www.frx.com
and also on the website www.streetevents.com.
Please log on to either website at least fifteen minutes prior to the
conference call as it may be necessary to download software to access
the call. A replay of the conference call will be available until
September 11, 2009 at both websites and also by dialing 1-800-642-1687
(US investors) or +1-706-645-9291 (international investors), Conference
Call ID 27580393.
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a
differentiated portfolio focused on branded medicines in
gastroenterology, respiratory and inflammatory diseases, pain,
osteoporosis and tissue management. An extensive range of OTC products
completes the portfolio. Its R&D is structured around partnerships and
in-licensing is a cornerstone of the company's growth strategy.
Nycomed employs 12,000 associates worldwide, and its products are
available in more than 100 countries. It has strong platforms in Europe
and in fast-growing markets such as Russia/CIS and Latin America. While
the US and Japan are commercialized through best-in-class partners,
Nycomed plans to further strengthen its own position in key Asian
markets.
Headquartered in Zurich, Switzerland, the company generated total sales
of €3.4 billion in 2008 and an adjusted EBITDA of €1.2 billion. For more
information visit www.nycomed.com.
|
Media:
|
|
General phone: +41 44 555 15 10
|
|
Beatrix Benz, phone: +41 79 218 9824
|
|
Tobias Cottmann, phone: +41 44 555 15 01
|
|
Investors:
|
|
Christian B. Seidelin, phone: +41 44 555 11 04
|
|
|
About Forest Laboratories
Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company
with a long track record of building partnerships and developing and
marketing products that make a positive difference in people’s lives. In
addition to its well-established franchises in therapeutic areas of the
central nervous and cardiovascular systems, Forest’s current pipeline
includes product candidates in all stages of development and across a
wide range of therapeutic areas. The company is headquartered in New
York, NY. To learn more about Forest Laboratories, visit www.frx.com.
Except for the historical information contained herein, this release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements involve a
number of risks and uncertainties, including the difficulty of
predicting FDA approvals, the acceptance and demand for new
pharmaceutical products, the impact of competitive products and pricing,
the timely development and launch of new products, and the risk factors
listed from time to time in Forest Laboratories’ Annual Report on Form
10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.
Source: Forest Laboratories, Inc.
Forest Laboratories, Inc.
Frank J. Murdolo, 1-212-224-6714
Vice
President - Investor Relations
frank.murdolo@frx.com